DK170139B1 - Anvendelse af dobbeltstrenget RNA til fremstilling af et middel til behandling af AIDS, fremgangsmåde til at gøre legemsvæsker eller blodlegemer resistente mod virusinfektion samt fremgangsmåde til fjernelse af vira - Google Patents

Anvendelse af dobbeltstrenget RNA til fremstilling af et middel til behandling af AIDS, fremgangsmåde til at gøre legemsvæsker eller blodlegemer resistente mod virusinfektion samt fremgangsmåde til fjernelse af vira Download PDF

Info

Publication number
DK170139B1
DK170139B1 DK405286A DK405286A DK170139B1 DK 170139 B1 DK170139 B1 DK 170139B1 DK 405286 A DK405286 A DK 405286A DK 405286 A DK405286 A DK 405286A DK 170139 B1 DK170139 B1 DK 170139B1
Authority
DK
Denmark
Prior art keywords
dsrna
cells
aids
interferon
virus
Prior art date
Application number
DK405286A
Other languages
Danish (da)
English (en)
Other versions
DK405286A (da
DK405286D0 (da
Inventor
William A Carter
Original Assignee
Hem Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hem Res Inc filed Critical Hem Res Inc
Publication of DK405286D0 publication Critical patent/DK405286D0/da
Publication of DK405286A publication Critical patent/DK405286A/da
Application granted granted Critical
Publication of DK170139B1 publication Critical patent/DK170139B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • External Artificial Organs (AREA)
DK405286A 1985-08-26 1986-08-26 Anvendelse af dobbeltstrenget RNA til fremstilling af et middel til behandling af AIDS, fremgangsmåde til at gøre legemsvæsker eller blodlegemer resistente mod virusinfektion samt fremgangsmåde til fjernelse af vira DK170139B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US76949485A 1985-08-26 1985-08-26
US76949485 1985-08-26
US88636386A 1986-07-17 1986-07-17
US88636386 1986-07-17

Publications (3)

Publication Number Publication Date
DK405286D0 DK405286D0 (da) 1986-08-26
DK405286A DK405286A (da) 1987-02-27
DK170139B1 true DK170139B1 (da) 1995-06-06

Family

ID=27118178

Family Applications (1)

Application Number Title Priority Date Filing Date
DK405286A DK170139B1 (da) 1985-08-26 1986-08-26 Anvendelse af dobbeltstrenget RNA til fremstilling af et middel til behandling af AIDS, fremgangsmåde til at gøre legemsvæsker eller blodlegemer resistente mod virusinfektion samt fremgangsmåde til fjernelse af vira

Country Status (7)

Country Link
EP (1) EP0213921B1 (zh)
JP (1) JPH0717510B2 (zh)
CN (1) CN1057231C (zh)
CA (1) CA1326450C (zh)
DE (1) DE3673288D1 (zh)
DK (1) DK170139B1 (zh)
IE (1) IE59277B1 (zh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU728984B2 (en) * 1987-03-03 2001-01-25 Hem Research, Inc. Syngeristic interplay of lymphokines and dsRNAs
PH24467A (en) * 1987-03-03 1990-07-18 Hem Res Inc Synergistics interplay of lymphokines and dsrnas
PH30882A (en) * 1987-03-03 1997-12-23 Hem Res Inc Activated Rnase L as a maker for viral infections.
US4950652A (en) * 1987-03-23 1990-08-21 Hem Research, Inc. dsRNAs for combination therapy in the treatment of viral diseases
ZA881639B (en) * 1987-03-23 1989-02-22 Hem Res Inc Treatment of human viral infection by dsrna combined with viral inhibitors
AU728894B2 (en) * 1987-07-17 2001-01-18 Hem Research, Inc. Double stranded RNA correction of aberrant metabolic pathways associated with uncontrolled tumor cell and virus growth cycles
AU1820388A (en) * 1987-07-17 1989-01-19 Hem Research, Inc. Double stranded rna correction of aberrant metabolic pathways associated with uncontrolled tumor cell and virus growth cycles
AU1820588A (en) * 1987-07-17 1989-01-19 Hem Research, Inc. Double-stranded rna correction of abnormalities in circulating immune complexes and monocyte function
IE72103B1 (en) * 1987-08-12 1997-03-12 Hem Res Inc Promotion of host defense by systemic dsRNA treatment
US5683986A (en) * 1987-08-12 1997-11-04 Hemispherx Biopharma Inc. Elaboration of host defense mediators into biological fluids by systemic dsRNA treatment
IE66830B1 (en) * 1987-08-12 1996-02-07 Hem Res Inc Topically active compositions of double-stranded RNAs
US5593973A (en) * 1987-09-04 1997-01-14 Hemispherx Biopharma Inc. Treatment of viral hepatitis with mismatched dsRNA
DE3853755T2 (de) * 1987-09-04 1995-12-14 Hem Pharma Corp Diagnose von Mangelzuständen doppelsträngiger RNS.
US4963532A (en) * 1987-11-25 1990-10-16 Hem Research, Inc. dsRNA-based prevention of viral escape
PH25365A (en) * 1987-12-23 1991-05-13 Hem Research Rhase l inhibitor as a marker for virus infections
CA1320446C (en) * 1988-06-20 1993-07-20 William A. Carter Modulation of lymphokine-resistant cellular states by dsrnas
ES2066847T3 (es) * 1988-07-07 1995-03-16 Hem Pharma Corp Diagnostico y tratamiento del sindrome de fatiga cronica.
ZA908037B (en) * 1989-10-11 1991-09-25 Hem Res Inc Protection from shock subsequent to injury by double-standed rnas
ATE147630T1 (de) * 1989-10-11 1997-02-15 Hem Pharma Corp Schutz gegen schock infolge einer schädigung durch doppelsträngige rna's
GB9108085D0 (en) * 1991-04-16 1991-06-05 Scras Complexes of polyadenylic acid with polyuridylic acid
FR2766715B1 (fr) * 1997-08-04 2001-02-16 Scras Produit comprenant au moins de l'arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique simultanee, separee ou etalee dans le temps, dans le traitement d'une maladie virale
FR2768345B1 (fr) * 1997-09-17 2001-05-04 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale, notamment d'une hepatite virale
FR2768344B1 (fr) * 1997-08-26 2001-02-16 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
EP1555317B1 (en) 1998-03-20 2011-09-28 Commonwealth Scientific And Industrial Research Organisation Synthetic genes and genetic constructs comprising the same
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US20020132257A1 (en) 2001-01-31 2002-09-19 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
EP1957101A4 (en) * 2005-12-07 2010-04-07 Hemispherx Biopharma DSRNA AS INFLUENZA VIRUS IMPFSTOFF ADJUVANTIES OR IMMUNOSTIMULATORS
AU2013206335B2 (en) * 2005-12-07 2017-05-04 Hemispherx Biopharma, Inc. dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants
CA3213217A1 (en) 2021-04-28 2022-11-03 Raphael Darteil Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1412591A (en) * 1971-11-30 1975-11-05 Beecham Group Ltd Antiviral ds rna and compositions thereof
DE3380200D1 (en) * 1982-09-16 1989-08-24 William Alvin Carter Anti-proliferative action of dsnras on tumor cells

Also Published As

Publication number Publication date
CN86105436A (zh) 1987-09-16
EP0213921B1 (en) 1990-08-08
EP0213921A3 (en) 1988-01-07
JPS6277334A (ja) 1987-04-09
EP0213921A2 (en) 1987-03-11
DE3673288D1 (de) 1990-09-13
IE862276L (en) 1987-02-26
DK405286A (da) 1987-02-27
CA1326450C (en) 1994-01-25
CN1057231C (zh) 2000-10-11
IE59277B1 (en) 1994-02-09
DK405286D0 (da) 1986-08-26
JPH0717510B2 (ja) 1995-03-01

Similar Documents

Publication Publication Date Title
DK170139B1 (da) Anvendelse af dobbeltstrenget RNA til fremstilling af et middel til behandling af AIDS, fremgangsmåde til at gøre legemsvæsker eller blodlegemer resistente mod virusinfektion samt fremgangsmåde til fjernelse af vira
US4795744A (en) Modulation of AIDS virus-related events by double-stranded RNAS
JP2656938B2 (ja) ｄｓＲＮＡと逆転写酵素インヒビターを含んで成るＨＩＶ感染治療のための医薬組成物
US5063209A (en) Modulation of aids virus-related events by double-stranded RNAs
Hammer et al. Synergistic activity of granulocyte-macrophage colony-stimulating factor and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro
US6093702A (en) Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
Hirsch et al. Treatment of human immunodeficiency virus infections
Berkhout et al. The antiviral activity of the milk protein lactoferrin against the human immunodeficiency virus type 1
US4820696A (en) Modulation of aids virus-related events by double-stranded RNAS
Tochikura et al. A biological response modifier, PSK, inhibits human immunodeficiency virus infection in vitro
CN1943782A (zh) 治疗禽流感感染
Yarchoan et al. Challenges in the therapy of HIV infection
Yarchoan et al. Clinical and basic advances in the antiretroviral therapy of human immunodeficiency virus infection
JPH07267874A (ja) Ｈｉｖ感染に対する組合せ化学療法
Fernández-Ortega et al. Non-induced leukocyte extract reduces HIV replication and TNF secretion
RU2290197C2 (ru) Фармацевтическое средство для лечения вич-инфекции, содержащая его композиция и способы его применения
CN1103221C (zh) 治疗人类免疫缺陷性病毒感染的药物
AU618525B2 (en) Activated rnase l as a marker for virus infections
CN102755335A (zh) 一种雷公藤甲素在制备治疗或预防艾滋病毒药物中的应用
Yarchoan et al. Correlations Between the In Vitro and In Vivo Activity of Anti-HIV Agents: Implications for Future Drug Deyelopment
WO1997037661A1 (fr) Medicament de prevention et de traitement des infections virales
Zeidner et al. Treatment of FeLV-induced immunodeficiency syndrome (FeLV-FAIDS) with controlled release capsular implantation of 2′, 3′-dideoxycytidine
Buimovici-Klein et al. Reverse transcriptase activity (RTA) in lymphocyte cultures of AIDS patients treated with HPA-23
Fischl Combination antiretroviral therapy for HIV infection
RU2021810C1 (ru) Способ воздействия на развитие заболевания, вызванного hiv-вирусом или вирусом, вызывающим сходную биохимическую или клиническую картину

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed

Country of ref document: DK